Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5 Methoxy N,n Dimethyltryptamine
2. 5-methoxy-n,n-dimethyltryptamine
3. Methoxydimethyltryptamine
4. Methoxydimethyltryptamines
5. Methylbufotenin
6. N,n Dimethyl 5 Methoxytryptamine
1. 1019-45-0
2. 5-methoxy-n,n-dimethyltryptamine
3. Methoxybufotenin
4. O-methylbufotenine
5. 5-meo-dmt
6. Meodmt
7. Methylbufotenine
8. 5-methoxydimethyltryptamine
9. 3-(2-dimethylaminoethyl)-5-methoxyindole
10. Bufotenine, O-methyl-
11. 2-(5-methoxy-1h-indol-3-yl)-n,n-dimethylethanamine
12. 1h-indole-3-ethanamine, 5-methoxy-n,n-dimethyl-
13. Ct 4334
14. Methoxydimethyltryptamines
15. 5-methoxy-n,n-dimethyl-1h-indole-3-ethanamine
16. Nsc 88624
17. 5-methoxy-n,n-dimethyl-1h-indole-3-ethylamine
18. Indole, 3-(2-(n,n-dimethylamino)ethyl)-5-methoxy-
19. X0mkx3gwu9
20. 3-(2-(n,n-dimethyl)aminoethyl)-5-methoxyindole
21. Chembl7257
22. Mls000069438
23. Chebi:2086
24. Indole, 3-(2-(dimethylamino)ethyl)-5-methoxy-
25. Indole, 3-[2-(dimethylamino)ethyl]-5-methoxy-
26. 3-[2-(n,n-dimethylamino)ethyl]-5-methoxy-indole
27. Nsc-88624
28. Smr000059066
29. 3-(2-(n,n-dimethylamino)ethyl)-5-methoxyindole
30. 3-[2-(n,n-dimethylamino)ethyl]-5-methoxyindole
31. 5-ome-dmt
32. Einecs 213-813-2
33. Unii-x0mkx3gwu9
34. Brn 0164771
35. Maybridge3_000045
36. Lopac-m-2381
37. Cid_1832
38. Lopac0_000724
39. Oprea1_596468
40. Gtpl145
41. 5-22-12-00027 (beilstein Handbook Reference)
42. Schembl132733
43. 2-(5-methoxy-1h-indol-3-yl)-n,n-dimethyl-ethanamine
44. Bdbm30707
45. Zinc57152
46. Dtxsid70144324
47. [2-(5-methoxy-1h-indol-3-yl)-ethyl]-dimethyl-amine
48. Hms1431c01
49. Hms2235c20
50. Hms3370m04
51. N,n-dimethyl-5-methoxy Tryptamine
52. Nsc88624
53. Pdsp1_000032
54. Pdsp1_000447
55. Pdsp2_000032
56. Pdsp2_000445
57. Stk368074
58. 5-methoxy-n-dimethyltryptamine
59. Akos005203483
60. Bufotenine, 5-methoxydimethyltryptamine
61. Ccg-204809
62. Db14010
63. Sdccgmls-0003129.p003
64. Idi1_011432
65. Wln: T56 Bmj D2n1&1 Go1
66. Ncgc00015654-01
67. Ncgc00015654-02
68. Ncgc00015654-03
69. Ncgc00015654-04
70. Ncgc00015654-05
71. Ncgc00015654-06
72. Ncgc00023288-03
73. Ncgc00023288-04
74. Indole,n-dimethylamino)ethyl]-5-methoxy-
75. Db-005455
76. N,n-dimethyl-5-methoxytryptamine, Free Base
77. C08309
78. D-5380
79. [2-(5-methoxy-1h-indol-3-yl)ethyl]dimethylamine
80. 019d450
81. 2-(5-methoxy-1h-indol-3-yl)ethyl-dimethyl-amine
82. 5-methoxyindole 3-(2-(n,n-dimethylamino)ethyl)
83. L000724
84. Q570757
85. 2-(5-methoxy-1h-indol-3-yl)-ethyl-dimethyl-amine
86. Brd-k34224286-001-07-1
87. 2-(5-methoxy-1h-indol-3-yl)-n,n-dimethylethanamine #
88. 5-meo-dmt Solution, 1.0 Mg/ml In Methanol, Certified Reference Material
| Molecular Weight | 218.29 g/mol |
|---|---|
| Molecular Formula | C13H18N2O |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | 218.141913202 g/mol |
| Monoisotopic Mass | 218.141913202 g/mol |
| Topological Polar Surface Area | 28.3 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 220 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
N,n-dimethyl-5-methoxytryptamine has known human metabolites that include Bufotenine.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Mebufotenin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mebufotenin, including repackagers and relabelers. The FDA regulates Mebufotenin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mebufotenin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Mebufotenin supplier is an individual or a company that provides Mebufotenin active pharmaceutical ingredient (API) or Mebufotenin finished formulations upon request. The Mebufotenin suppliers may include Mebufotenin API manufacturers, exporters, distributors and traders.
Mebufotenin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mebufotenin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mebufotenin GMP manufacturer or Mebufotenin GMP API supplier for your needs.
A Mebufotenin CoA (Certificate of Analysis) is a formal document that attests to Mebufotenin's compliance with Mebufotenin specifications and serves as a tool for batch-level quality control.
Mebufotenin CoA mostly includes findings from lab analyses of a specific batch. For each Mebufotenin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mebufotenin may be tested according to a variety of international standards, such as European Pharmacopoeia (Mebufotenin EP), Mebufotenin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mebufotenin USP).
LOOKING FOR A SUPPLIER?
